Nadinda A M van der Ende, Bob Roozenbeek, Lucas E M Smagge, Sven P R Luijten, Leo A M Aerden, Petra Kraayeveld, Ido R van den Wijngaard, Geert J Lycklama À Nijeholt, Heleen M den Hertog, H Zwenneke Flach, Alexis C Wallace, Victor Gurewich, Gregory J Del Zoppo, William J Meurer, Hester F Lingsma, Aad van der Lugt, Diederik W J Dippel
BACKGROUND: The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction with alteplase. Therefore, this treatment has the potential to be safer and more efficacious than treatment with alteplase alone. The aim of this study is to assess the safety and efficacy of thrombolytic treatment consisting of a small bolus alteplase followed by m-proUK compared with standard thrombolytic treatment with alteplase in patients presenting with ischemic stroke...
August 9, 2022: Trials